8-K: Aclarion Secures $10.36M in Registered Direct Offering

Aclarion, Inc. announced a registered direct offering of common stock and pre-funded warrants, expecting to raise approximately $10.36 million for market and product development.

Summary

• Aclarion, Inc. entered into a Securities Purchase Agreement on January 8, 2026, for a registered direct offering.
• The offering includes the sale of 200,000 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $5.18 per share.
• Pre-funded warrants to purchase up to 1,800,000 shares of Common Stock were also sold.
• These pre-funded warrants are immediately exercisable at a nominal exercise price of $0.00001 per share.
• Purchasers of pre-funded warrants are subject to a beneficial ownership limitation of 4.99% or 9.99% of outstanding common stock, which can be adjusted with 61 days' prior notice.
• The aggregate gross proceeds to the company from the offering are expected to be approximately $10.36 million, before deducting placement agent fees and other estimated offering expenses.
• The offering is expected to close on or about January 9, 2026, subject to customary closing conditions.
• Dawson James Securities, Inc. is serving as the exclusive placement agent, receiving a 6.0% cash fee of the aggregate gross proceeds and reimbursement for certain expenses.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding for strategic initiatives, which is positive for long-term growth. However, the associated dilution from the issuance of shares and warrants, along with the costs of the offering, temper the immediate positive impact. The use of pre-funded warrants with a nominal exercise price suggests a strong incentive for investors to convert, leading to future dilution.

Positives

• Secured approximately $10.36 million in gross proceeds, which will strengthen the company's financial position.
• Proceeds are earmarked for strategic growth initiatives including market development, clinical evidence (The Clarity Trial), and product development and quality.
• The offering is a registered direct offering, indicating a structured and compliant capital raise under an effective S-3 registration statement.

Negatives

• The issuance of new shares and warrants will result in dilution for existing shareholders.
• Placement agent fees of 6.0% of gross proceeds and other offering expenses will reduce the net proceeds available to the company.

Risks

• General market conditions could impact the company's ability to complete the offering on favorable terms, or at all.
• The company's ability to successfully execute on its market development, clinical evidence (The Clarity Trial), and product development plans is subject to various uncertainties.
• Potential for further dilution for existing shareholders upon the exercise of the pre-funded warrants.
• Other risks detailed from time to time in the company's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Future Outlook

The company expects to complete the offering on or about January 9, 2026, and intends to use the net proceeds to fund market development, clinical evidence (The Clarity Trial), product development and quality, and general and administration support, as well as other general corporate purposes.

Management Comments

• Management intends to use the net proceeds from the Offering to fund market development and clinical evidence, The Clarity Trial, product development and quality, and general and administration support, and other general corporate purposes.

Industry Context

This capital raise provides Aclarion with additional funding to advance its strategic initiatives, particularly in market and product development, which is crucial for companies in the Medtech sector to innovate and expand their reach. The focus on 'The Clarity Trial' suggests a commitment to clinical validation, a key differentiator in the medical technology industry.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new common stock and the future exercise of pre-funded warrants.
• Company (Aclarion, Inc.): Gains significant capital to fund strategic growth initiatives, potentially improving long-term prospects.
• Investors (Purchasers in Offering): Acquire common stock and pre-funded warrants, with potential for future gains if the company's strategy is successful.
• Placement Agent (Dawson James Securities, Inc.): Receives a 6.0% cash fee and expense reimbursement for facilitating the offering.

Next Steps

• Closing of the offering on or about January 9, 2026.
• Filing of a prospectus supplement with the SEC on January 9, 2026.
• Application to list the newly issued shares and pre-funded warrant shares on the Nasdaq Stock Market.
• Continued funding of market development, The Clarity Trial, and product development.

Key Dates

Recommendation

The capital raise provides Aclarion with crucial funding for its strategic initiatives, including market and product development and clinical trials, which is a positive for the company's long-term viability and growth prospects. However, the offering involves significant dilution for existing shareholders through the issuance of new common stock and pre-funded warrants. While the funding is beneficial, the immediate dilutive effect and the costs associated with the offering suggest a 'hold' recommendation, allowing investors to assess the company's execution of its funded strategies and the market's absorption of the new shares before making further investment decisions.

Keywords

Aclarion, ACON, SEC Filing, 8-K, Registered Direct Offering, Common Stock, Pre-funded Warrants, Capital Raise, Equity Offering, Market Development, Clinical Trials, Product Development, Dilution, Nasdaq